

Cortellis

Find expert insights in patents

The Cortellis editorial team reads through 100's of patents every week to provide you with insights from the pharmaceutical industry. This information is gathered and enhanced by experts and made available to you in patent records and results pages.

Regardless of your background and level of expertise in patents, you'll find these insights useful for commercial context and for identifying specific innovations that are protected, as well as other relevant patents related to the same topic/holder/product. In addition, editors highlight important facts like the first time a company is filing a patent in a new field or for a given target, providing you with very early competitive intelligence.

Follow these steps to display patent annotations and other insights in your results page:

1. Once you have searched and filtered your results, select 'Abstract View' at the top right of the results page.

362 results found for index Search for the search term "crohns disease" with filter(s) applied: Last 12 months; Crohns disease

First Previous **1** 2 3 4 5 6 7 8 9 10 Next Last

Results Per page: 25 Sort by: Relevance Order Columns View

Patent Number	Title	Owner Companies	Indications	Target-based Actions	Patent Type
WO-2020006629	Compounds for treatment of inflammatory bowel disease and methods thereof	Algenon Pharmaceuticals	Crohns disease; Inflammatory bowel disease; Ulcerative colitis	Noncompetitive NMDA antagonist	New use

2. With just one click, you'll be able to evaluate competitors' patents by reading more meaningful and self-explanatory titles, specific details on the innovation protected and annotations to provide commercial context.

Results Per page: 25 Sort by: Last Change Date Most Recent Order Columns View

[WO-2020012177](#) [Expand all](#)

Enhanced Title	Vaccine comprising a polypeptide from <i>Mycobacterium avium</i> subspecies paratuberculosis – useful for preventing/treating <i>Mycobacterium</i> infection or its symptom.
Title	Immunogenic composition for paratuberculosis
Abstract Classification	Anti-Infectives; Biologicals and Immunologicals; Cardiovascular and Renal; C Endocrine and Metabolic; Pharmaceuticals; Pulmonary-Allergy, Dermatologica
Owner Companies	HAV Vaccines Ltd; Individual
Novelty	The use of a vaccine comprising a polypeptide from <i>Mycobacterium avium</i> subspecies paratuberculosis (MAP) or a polynucleotide encoding said polypeptide treating or preventing MAP infection or a symptom associated with MAP (eg Crohn's disease, Thyroiditis, Sarcoidosis, Parkinson's disease, Type 1 diabetes, leprosy or irritable bowel syndrome) is claimed. A peptide, a polypeptide, a polynucleotide encoding the peptide or the polypeptide, a vaccine vector comprising the polynucleotide encoding the polypeptide comprising MAP 900 are claimed. Methods of treating or preventing MAP infection or its symptoms comprises administering the polypeptides, the polynucleotides, the peptide, or the or a vaccine vector are claimed. A kit for treating or preventing MAP infection or its symptoms is claimed.
Annotation	Vaccine comprising a polypeptide of <i>Mycobacterium</i> subspecies paratuberculosis P900. Useful in eliciting immune response against MAP infection or its associated symptom such as Crohn's disease, Johne's disease and ulcerative colitis. University of Oxford, The Jenner Institute and HAV Vaccines are developing ChAdOx2-HA V (as of January 2020, in phase 1), a replication-deficient simian adenoviral vector vaccine expressing the MAP antigens ahpC, gsd, p12 and mpa, for the treatment of Crohn's disease. Appear to be the first filing on vaccines from the assignee. However, see WO2007017635 from the inventor, covering immunogenic constructs for treating MAP infections. At the time of publication, Hermon-Taylor was also based at Crohn's MAP Vaccine and King's college London.

Cortellis can help you identify the first time a company is filing a patent in a new field or for a given target, providing you with very early competitive intelligence.

3. Derwent abstracts, comments on biology and chemistry, as well as IPC codes, Manual codes and additional insights can be found in the patent report – which you can access by clicking the patent code.

WO-2020012177	
Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms < Previous Next >
Companies and Drugs	EDITORIAL ABSTRACT
Editorial Abstract	Summary Abstract
Summary Abstract	Document Written From: WO-2020012177
DWPI Abstract	Enhanced Title: Vaccine comprising a polypeptide from <i>Mycobacterium avium</i> subspecies paratuberculosis – useful for preventing/treating <i>Mycobacterium</i> infection or its symptom.
Chemical Structures	Abstract Classification: Anti-Infectives ; Biologicals and Immunologicals ; Cardiovascular and Renal ; Central and Peripheral Nervous Systems ; Oncologic, Endocrine and Metabolic ; Pulmonary-Allergy, Dermatological and Anti-Inflammatory ; Pharmaceuticals
Claims	Novelty: The use of a vaccine comprising a polypeptide from <i>Mycobacterium avium</i> subspecies paratuberculosis (MAP) or a polynucleotide encoding said polypeptide treating or preventing MAP infection or a symptom associated with MAP (eg Crohn's disease, Thyroiditis, Sarcoidosis, Parkinson's disease, Type 1 diabetes, leprosy or irritable bowel syndrome) is claimed. A peptide, a polypeptide, a polynucleotide encoding the peptide or the polypeptide, a vaccine vector comprising the polynucleotide encoding the polypeptide comprising MAP 900 are claimed. Methods of treating or preventing MAP infection or its symptoms comprises administering the polypeptides, the polynucleotides, the peptide, or the or a vaccine vector are claimed. A kit for treating or preventing MAP infection or its symptoms is claimed.
Documents and Status	Advantage: The hAd5 HAV vaccines are safe, immunogenic, non-toxic and maximises the efficacy of therapeutic vaccination.
Expiry	Biology: <i>In vivo</i> studies were performed to assess the efficacy and protective effect of HAV vaccines against MAP infection in bovine calves. Specific cellular immune responses to HAV vaccine peptides were seen in all HAV vaccinated animals two weeks after boosting and were maintained throughout the study. All HAV vaccinated calves appeared to eliminate MAP from blood and blocked detectible faecal shedding (example 1, pages 64-67).
	Examples: Methods of constructing hAd5 HAV vaccine peptides were presented (example 4, page 87).
	Chemistry: Sequences provided in source document.
	Compound Name: None Given

DWPI Abstract	
Document Written From	WO-2020012177
Detailed Description	INDEPENDENT CLAIMS are included for the following: a peptide of up to 100 amino acids, which comprises amino acid (SEQ ID NO: Not defined), given in the specification; a vaccine vector, which comprises a polynucleotide encoding a polypeptide comprising an amino acid sequence of 9 contiguous amino acids from region of MAP P900 having amino acid (SEQ ID NO: 2); a method for treating or preventing MAP infection or a condition or symptom associated with MAP infection, which involves administering subject with an effective amount of a polypeptide, or a polynucleotide encoding polypeptide, a peptide consist of amino acid sequence, a peptide, or a vaccine vector; and a kit for treating or preventing MAP infection or a condition or symptom associated with MAP infection, which comprises polypeptide, or a polynucleotide encoding polypeptide, a peptide, or vaccine vector and other therapeutic agent for simultaneous, sequential or separate use.
Activity	Antiinflammatory; Gastrointestinal-Gen; Antibacterial; Antiulcer; Antipsoriatic; Antithyroid; Antiparkinsonian; Neuroprotective; Antidiabetic; Antiarthritic; Antirheumatic; Nootropic; Antileprotic; Muscular-Gen; Immunomodulator. No biological data given.
Mechanism of Action	Vaccine.
Tech Focus	BIOTECHNOLOGY Preferred Conditions: The polypeptide comprises amino acid sequence (SEQ ID NO: Not defined), given in the specification. The polypeptide comprises amino acid sequence (SEQ ID NO: Not defined), which are MVINDDAQRL[ps]QR. The vaccine comprises two or more polypeptides comprising an amino acid sequence of 9 contiguous amino acids from region of MAP P900 having amino acid (SEQ ID NO: 2), or two or more polynucleotides encoding polypeptides. The vaccine comprises a polypeptide comprising amino acid sequence (SEQ ID NO: Not defined), given in the specification. The vaccine comprises two of polypeptides or polynucleotides, where polypeptide comprises the amino acid sequence (SEQ ID NO: Not defined), given in the specification, or a polynucleotide encoding polypeptide. The polypeptide and peptide comprises amino acid sequence (SEQ ID NO: Not defined), which are MVINDDAQRLSQRX 2 VTTLADGGVETWAIID. MVINDDAQRLSQRX 2 VTTLADGGVETWAIIDLNA. MVINDDAQRLSORVANDEAALLEX 2 VTTLADGGVETWAIID.

For more information contact Customer Service at [LS Product Support](#)